Cargando…

Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations

Detalles Bibliográficos
Autores principales:	Abo-Helo, Nizar, Muhammad, Emad, Ghaben-Amara, Sondus, Cohen, Shai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983475/ https://www.ncbi.nlm.nih.gov/pubmed/35398265 http://dx.doi.org/10.1016/j.anai.2022.03.035

Ejemplares similares

Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination
por: Abo-helo, Nizar, et al.
Publicado: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Kahn, Benjamin, et al.
Publicado: (2021)

Perinatally Human Immunodeficiency Virus–Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity( )
por: Morrocchi, Elena, et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination
por: Kim, A-Sol, et al.
Publicado: (2023)

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
por: Ammitzbøll, Christian, et al.
Publicado: (2021)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
por: Eduarda Andrade e Andrade, Maria, et al.
Publicado: (2022)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Nishiguchi, Yamato, et al.
Publicado: (2021)

Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
por: Greco, Marilena, et al.
Publicado: (2021)

Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study
por: Tau, Luba, et al.
Publicado: (2023)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
por: Ballman, Madison, et al.
Publicado: (2021)

Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission
por: Bixio, Riccardo, et al.
Publicado: (2021)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents
por: Canaday, David H, et al.
Publicado: (2021)

IgG4-related disease: case report and literature review
por: Nizar, Abo-Helo, et al.
Publicado: (2015)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Wu, Xiaotian, et al.
Publicado: (2021)

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
por: Nir, Omer, et al.
Publicado: (2022)

Long-term evaluation of sperm parameters after coronavirus disease 2019 messenger ribonucleic acid vaccination
por: Diaz, Parris, et al.
Publicado: (2022)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Takada, Kazuki, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients
por: La Civita, Evelina, et al.
Publicado: (2023)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Ricardo, Jose W., et al.
Publicado: (2021)

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients
por: Schramm, René, et al.
Publicado: (2021)

Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years
por: Toepfner, Nicole, et al.
Publicado: (2022)

Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
por: Velasco, María, et al.
Publicado: (2021)

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study
por: Tomkins-Netzer, Oren, et al.
Publicado: (2022)

BNT162b2 coronavirus disease-2019 vaccination accelerated rheumatoid arthritis disease activity in chronic eosinophilic pneumonia: A case report
por: Morikawa, Moeko Murano, et al.
Publicado: (2022)

Acute cervical dystonia following the BNT162b2 mRNA COVID-19 vaccine
por: Algahtani, Hussein A., et al.
Publicado: (2022)

A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency
por: Mullur, Jyotsna, et al.
Publicado: (2021)

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)
por: Li, Xue, et al.
Publicado: (2023)

Immune thrombocytopenia in 2 healthy young women after the Pfizer‐BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination
por: Collins, Emilie C., et al.
Publicado: (2021)

Detection of neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines
por: Romano, Ciro, et al.
Publicado: (2021)

Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency
por: Goda, Vera, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019
por: Fill, Lauren, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_es1cd7jqqsm5jpb0iitop318ah